# Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

> **NCT04363164** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 150 (estimated)

## Conditions studied

- Castration Resistant Metastatic Prostate Cancer

## Interventions

- **DRUG:** Testosterone cypionate
- **DRUG:** Enzalutamide
- **DRUG:** Testosterone enanthate

## Key facts

- **NCT ID:** NCT04363164
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-19
- **Primary completion:** 2026-07
- **Final completion:** 2027-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04363164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04363164, "Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04363164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*